These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3745986)

  • 1. Pharmacokinetics and tissue distribution of recombinant human alpha A, D, A/D(Bgl), and I interferons and mouse alpha-interferon in mice.
    Bohoslawec O; Trown PW; Wills RJ
    J Interferon Res; 1986 Jun; 6(3):207-13. PubMed ID: 3745986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of recombinant murine interferon-gamma and human interferon-alpha A/D(Bgl) administered in concert and their influence on natural killer cell function in mice.
    Chen SA; Shalaby MR; Crase DR; Palladino MA; Baughman RA
    J Interferon Res; 1988 Oct; 8(5):597-608. PubMed ID: 3148670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orally administered interferons suppress bone marrow function.
    Koren S; Fleischmann WR
    Proc Soc Exp Biol Med; 1993 Nov; 204(2):155-64. PubMed ID: 8415770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human interferon-alpha A/D enhances the expression of Ly-6A/E, Ly-6C, and TAP antigens on murine T lymphocytes.
    Dumont FJ
    J Interferon Res; 1988 Jun; 8(3):347-56. PubMed ID: 2842413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of 125I-interferons in pharmacokinetic and tissue distribution studies.
    Palleroni AV; Bohoslawec O
    J Interferon Res; 1984; 4(4):493-8. PubMed ID: 6501942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of human recombinant interferon-alpha I after i.v. infusion and im injection in African green monkeys.
    Wills RJ; Soike KF
    J Interferon Res; 1988 Aug; 8(4):427-32. PubMed ID: 3171243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells.
    Brunda MJ; Tarnowski D; Davatelis V
    Int J Cancer; 1986 May; 37(5):787-93. PubMed ID: 2422129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of experimentally-induced murine metastases by recombinant alpha interferon: correlation between the modulatory effect of interferon treatment on natural killer cell activity and inhibition of metastases.
    Brunda MJ; Rosenbaum D; Stern L
    Int J Cancer; 1984 Sep; 34(3):421-6. PubMed ID: 6480158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, tissue distribution, and cell localization of [35S]methionine-labeled recombinant human and murine alpha interferons in mice.
    Johns TG; Kerry JA; Veitch BA; Mackay IR; Tutton PJ; Tymms MJ; Cheetham BF; Hertzog PJ; Linnane AW
    Cancer Res; 1990 Aug; 50(15):4718-23. PubMed ID: 2369745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nephrectomy on the pharmacokinetics of various cloned human interferons in the rat.
    Tokazewski-Chen SA; Marafino BJ; Stebbing N
    J Pharmacol Exp Ther; 1983 Oct; 227(1):9-15. PubMed ID: 6620174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of radiation cytotoxicity by recombinant interferons, a phenomenon associated with increased blockage at the G2-M phase of the cell cycle.
    Chang AY; Keng PC
    Cancer Res; 1987 Aug; 47(16):4338-41. PubMed ID: 2440565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral activity of a novel recombinant human interferon-alpha B/D hybrid.
    Gangemi JD; Lazdins J; Dietrich FM; Matter A; Poncioni B; Hochkeppel HK
    J Interferon Res; 1989 Apr; 9(2):227-37. PubMed ID: 2541210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different pharmacokinetics between natural and recombinant human interferon beta in rabbits.
    Satoh YI; Kasama K; Kajita A; Shimizu H; Ida N
    J Interferon Res; 1984; 4(3):411-22. PubMed ID: 6491398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sensitivity of different cell lines to interferons: the relative antiviral activity as a function of the interferon subtype].
    Tonew M; Glück B; Ohme E; Wondraczek RH
    J Basic Microbiol; 1989; 29(8):537-45. PubMed ID: 2559962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of interferon or Propionibacterium acnes on the course of experimentally induced feline infectious peritonitis in specific-pathogen-free and random-source cats.
    Weiss RC; Cox NR; Oostrom-Ram T
    Am J Vet Res; 1990 May; 51(5):726-33. PubMed ID: 2159739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Type I Interferon Subtypes and Interferon-Gamma in Type I Interferon Diabetes Inhibitory Activity in the NOD Mouse.
    Sobel D; Ahvazi B; Pontzer C
    J Interferon Cytokine Res; 2016 Apr; 36(4):238-46. PubMed ID: 26716812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Native human IFN-alpha is a more potent suppressor of HDF response to profibrotic stimuli than recombinant human IFN-alpha.
    Santak G; Santak M; Forcić D
    J Interferon Cytokine Res; 2007 Jun; 27(6):481-90. PubMed ID: 17572012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of interferon-beta activity by fibroblast cells.
    Ramamurthy V; Fleischmann WR
    Antiviral Res; 1986 Aug; 6(5):267-75. PubMed ID: 3094445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orally administered interferons exert their white blood cell suppressive effects via a novel mechanism.
    Fleischmann WR; Koren S; Fleischmann CM
    Proc Soc Exp Biol Med; 1992 Nov; 201(2):200-7. PubMed ID: 1384066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
    Pearson JW; Fogler WE; Volker K; Riggs CW; Gruys E; Groves ES; Wiltrout RH; Longo DL
    J Natl Cancer Inst; 1993 Jun; 85(11):907-12. PubMed ID: 8492319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.